Pediatric Hematology
Contributions
Type: Publication Only
Background
Improvement in long-term survival in patients with acute childhood leukemia has led to the need for monitorization of chemotherapy related morbidity and mortality.
Aims
This study aimed to evaluate long-term endocrine compliations in acute lymphoblastic leukemia survivors.
Methods
Sixty patients diagnosed with acute lymphoblastic leukemia between December 2003 and May 2009 at Pediatric Hematology Clinic, Ankara Children's Hematology and Oncology Education and Research Hospital, who were in remission for at least two years, were evaluated retrospectively for endocrine complications.
Results
There were 31 male and 29 female patients, while 55 of them were diagnosed with precursor B-cell ALL and 5 of them with T-cell ALL. Median age of the patients at the time of diagnosis, at the time of chemotherapy completion and at the time of study was 5 years (range:3-7,8 years), 8 years (6,2-10,8 years) and 11.7 years (range: 10 - 14.9 years), respectively and median duration of remission was 4 years (range: 2.5-5 years). At least one complication was observed in 81,6% of patients. Vitamin D insufficiency / deficiency (46,6%), overweight / obesity (33,3%) and dyslipidemia (23,3%) were the most three frequent endocrine complications. Other complications seen in our patients were hyperparathyroidism secondary to vitamin D deficiency (15%), insulin resistance (11,7%), hypertension (8,3%), failure to thrive (6,7%), thyroid function abnormality (5%), precocious puberty (3,3%) and decreased bone mineral density (1,7%), respectively. There were no statistically significant correlation between endocrine complications and age, sex and radiotherapy.
Summary
A high frequency of endocrine complications were observed in the current study. It is estimated that about two-thirds of cancer survivors will experience at least one late adverse effects and more than 40% may have a severe, disabling or life-threatening condition or may die 30 years after cancer is diagnosed as a result of their cancer and it’s therapy. The high frequency of late effects necessitates long-term surveillance of this population to better understand the incidence of late-occurring events and defining high-risk features that can facilitate developing intervention strategies for early detection and prevention.
Keyword(s): Acute lymphoblastic leukemia, Children, Late effects
Session topic: Publication Only
Type: Publication Only
Background
Improvement in long-term survival in patients with acute childhood leukemia has led to the need for monitorization of chemotherapy related morbidity and mortality.
Aims
This study aimed to evaluate long-term endocrine compliations in acute lymphoblastic leukemia survivors.
Methods
Sixty patients diagnosed with acute lymphoblastic leukemia between December 2003 and May 2009 at Pediatric Hematology Clinic, Ankara Children's Hematology and Oncology Education and Research Hospital, who were in remission for at least two years, were evaluated retrospectively for endocrine complications.
Results
There were 31 male and 29 female patients, while 55 of them were diagnosed with precursor B-cell ALL and 5 of them with T-cell ALL. Median age of the patients at the time of diagnosis, at the time of chemotherapy completion and at the time of study was 5 years (range:3-7,8 years), 8 years (6,2-10,8 years) and 11.7 years (range: 10 - 14.9 years), respectively and median duration of remission was 4 years (range: 2.5-5 years). At least one complication was observed in 81,6% of patients. Vitamin D insufficiency / deficiency (46,6%), overweight / obesity (33,3%) and dyslipidemia (23,3%) were the most three frequent endocrine complications. Other complications seen in our patients were hyperparathyroidism secondary to vitamin D deficiency (15%), insulin resistance (11,7%), hypertension (8,3%), failure to thrive (6,7%), thyroid function abnormality (5%), precocious puberty (3,3%) and decreased bone mineral density (1,7%), respectively. There were no statistically significant correlation between endocrine complications and age, sex and radiotherapy.
Summary
A high frequency of endocrine complications were observed in the current study. It is estimated that about two-thirds of cancer survivors will experience at least one late adverse effects and more than 40% may have a severe, disabling or life-threatening condition or may die 30 years after cancer is diagnosed as a result of their cancer and it’s therapy. The high frequency of late effects necessitates long-term surveillance of this population to better understand the incidence of late-occurring events and defining high-risk features that can facilitate developing intervention strategies for early detection and prevention.
Keyword(s): Acute lymphoblastic leukemia, Children, Late effects
Session topic: Publication Only